Insilico secures $888million Servier partnership for AI oncology

Insilico Medicine, a world-leading artificial intelligence (AI)-driven drug discovery company, has announced a multi-year research and development (R&D) collaboration with independent international pharmaceutical company, Servier. The partnership is designed to identify and develop novel therapeutics for difficult-to-drug targets in oncology, using Insilico’s proprietary AI platform, Pharma.AI.

The collaboration aims to integrate advanced AI technologies into early-stage drug discovery, which is a growing trend in the pharmaceutical industry, particularly in cancer, where unmet medical needs remain significant.

Financial terms and division of responsibilities

Under the terms of the agreement, Insilico will be eligible to receive up to US$32 million in upfront and near-term R&D payments. The company will lead the AI-driven discovery and development of potential drug candidates that meet predefined criteria. Servier, meanwhile, will share R&D expenses and take responsibility for clinical validation and the commercialisation of any successful therapies.

The structure of the collaboration combines Insilico’s strength in AI-enabled discovery with Servier’s global experience in clinical development and bringing medicines to market.

“This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico’s internally developed and validated AI platform”, said Christophe Thurieau, Executive Director of Research at Servier.

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, have announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and developing novel therapeutics for challenging targets in the oncology space by leveraging Insilico’s proprietary AI platform, Pharma.AI. Credit: Insilico Medicine

Confidence in AI-powered drug discovery

For Insilico, the agreement represents further validation of its approach to integrating generative AI across the pharmaceutical value chain. The company has positioned its Pharma.AI platform as a comprehensive system capable of target identification, molecule generation and optimisation, and preclinical development.

“I am excited to see the collaboration – it is yet another strong acknowledgment of our AI capabilities and R&D expertise”, said Dr Alex Zhavoronkov, founder, CEO and CBO of Insilico Medicine. “As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter and safer drug development.”

Expanding oncology pipeline and clinical progress

Insilico brings substantial oncology experience to the partnership. The company has built a broad pipeline targeting multiple cancer indications, spanning both moderately novel and well-established biological mechanisms. Among its leading assets are the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, both of which are currently being evaluated in global, multicentre Phase I clinical trials.

In addition, four other oncology programmes have been fully or partially out licensed to partners, with Phase I trials actively under way.

Redefining timelines in preclinical development

By combining state-of-the-art AI and automation technologies, Insilico reports significant improvements in the efficiency of preclinical drug development. Traditional early-stage drug discovery typically takes an average of 4.5 years. In contrast, between 2021 and 2024 Insilico nominated 20 preclinical candidates, achieving an average timeline of just 12 to 18 months from project initiation to preclinical candidate nomination.

Each programme required only 60 to 200 molecules to be synthesised and tested, setting a new benchmark for AI-driven drug R&D, underlining the potential impact of AI on accelerating innovation in oncology.